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Abstract
Background—Although a well-established causative relationship exists between smoking and 
several epithelial cancers, the association of smoking with metastatic progression in melanoma is 
not well studied. We hypothesized that smokers would be at increased risk for melanoma 
metastasis as assessed by sentinel lymph node (SLN) biopsy.
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Methods—Data from the first international Multicenter Selective Lymphadenectomy Trial 
(MSLT-I) and the screening-phase of the second trial (MSLT-II) were analyzed to determine the 
association of smoking with clinicopathologic variables and SLN metastasis.
Results—Current smoking was strongly associated with SLN metastasis (p = 0.004), even after 
adjusting for other predictors of metastasis. Among 4231 patients (1025 in MSLT-I and 3206 in 
MSLT-II), current or former smoking was also independently associated with ulceration (p < 0.001 
and p < 0.001, respectively). Compared with current smoking, never smoking was independently 
associated with decreased Breslow thickness in multivariate analysis (p = 0.002) and with a 0.25 
mm predicted decrease in thickness.
Conclusion—The direct correlation between current smoking and SLN metastasis of primary 
cutaneous melanoma was independent of its correlation with tumor thickness and ulceration. 
Smoking cessation should be strongly encouraged among patients with or at risk for melanoma.
Smoking is a known preventable cause of cancer mortality.1 Based on estimates from the 
World Health Organization, by 2020, 8.4 million people will die each year from tobacco-
related diseases and over 100 million people died from tobacco-related diseases in the 20th 
century.1, 2 Counterintuitively, smoking does not appear to be associated with an increased 
incidence of melanoma, and there may even be a protective effect, although these data are 
controversial.3–8 Few studies have evaluated the impact of smoking on the progression of 
primary cutaneous melanoma, and many clinical trials in oncology do not collect smoking 
data unless smoking is thought to contribute to disease pathogenesis.9 Studies assessing the 
association of smoking with nodal metastasis in melanoma are limited and predate modern 
methods of nodal assessment with sentinel lymph node biopsy (SNB). We undertook this 
study to determine if smoking is associated with the early, subclinical phase of metastasis, as 
assessed by a melanoma-positive sentinel lymph node (SLN).
METHODS
The Multicenter Selective Lymphadenectomy Trials are prospective international trials 
evaluating methods of lymph node management in patients with clinically localized 
cutaneous melanomas. Data for this analysis were derived from patients in the entire MSLT-I 
trial (NCT00275496) and the screening phase of the MSLT-II trial (NCT00297895).11 The 
MSLT-I study compared treatment by wide local excision alone versus wide local excision 
with sentinel node biopsy and immediate completion lymph node dissection for SLN 
metastases.11 Since only one arm of the study underwent SLN assessment, this analysis 
includes only that group. The screening phase of MSLT-II enrolled patients prior to SLN 
biopsy with clinically localized melanoma at least 1.2 mm in thickness or with invasion to at 
least Clark’s level IV. Patients who were found to have SLN metastases by standard 
pathology or multimarker quantitative reverse transcriptase-polymerase chain reaction (RT-
PCR) were eligible for entry into the randomized phase of the trial, which is currently closed 
to accrual and ongoing.
Smoking status was recorded at trial enrollment either via patient questionnaire or intake 
interview. Patients were categorized as current, former, or never smokers; the smoking group 
included tobacco inhaled via cigarette, pipe, cigar or other source. Subjects with incomplete 
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data regarding smoking history, Breslow thickness, ulceration status, primary site, or receipt 
of SNB for MSLT-I patients were excluded (n = 2732). Subjects provided written informed 
consent for participation in the clinical trials and, for the current analysis, were de-identified 
and independently determined to be exempt from Institutional Review Board review.
Demographic and clinicopathologic factors examined in this study included age, sex, 
ulceration, Breslow thickness, primary site, and SLN status. These factors were compared 
between the three smoking groups using the Chi-square test for categorical variables and the 
Wilcoxon rank sum test for continuous variables such as age and Breslow thickness. 
Multivariate analysis was conducted for all factors associated with ulceration and again for 
factors associated with Breslow thickness. Finally, a logistic regression model for 
clinicopathologic factors associated with SLN metastasis was created (Table 3). We utilized 
SAS software version 9.3 (SAS Institute, Cary, NC, USA) for all analyses. A two-sided p-
value of ≤ 0.05 was considered significant.
RESULTS
The 4231 subjects included 1025 patients from MSLT-I and 3206 patients from MSLT-II 
(Table 1). Current smokers (N = 719) were significantly younger than former smokers (N = 
1100) or never smokers (N = 2412). Current smokers also had more ulcerated lesions than 
former smokers or never smokers. In addition, former smokers were more likely to be male 
than never smokers or current smokers, and never smokers had thinner lesions than former 
smokers or current smokers. There was a difference in primary site distribution between 
head/neck, extremity and truncal lesions based on smoking status; however, there was no 
difference in melanoma site between current and former smokers or between former and 
never smokers. Finally, current smokers were significantly more likely to have SLN 
metastasis when all three groups were compared (Fig. 1), or when current smokers were 
compared separately to never smokers, and even former smokers.
Logistic regression analysis showed that both current smoking and former smoking were 
independently associated with ulceration (Table 1). Multivariate regression analysis revealed 
an association between smoking and Breslow thickness (Table 2); never smoking was 
associated with a 0.25 mm decrease in Breslow thickness relative to current smoking, 
independent of other variables. Breslow thickness was 1.2 mm higher if the lesion was 
ulcerated, and thickness increased by 0.01 mm with each year of age. Breslow thickness was 
0.15 mm less for females than males.
On univariable analysis, current smoking (compared with never smoking) was significantly 
associated with SLN positivity, and this factor remained significant at multivariable analysis 
(Table 3). In these analyses, increasing age was significantly associated with a small 
decrement in risk of SLN positivity. Ulceration and Breslow thickness were also associated 
with increased SLN positivity in multivariable analysis. In this analysis, there was also a 
significant shift towards SLN positivity in truncal tumors as opposed to head and neck 
tumors.
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DISCUSSION
In a large sample of patients from two international, prospective, randomized clinical trials, 
current smoking was strongly associated with SLN metastasis, even after adjusting for other 
predictors of melanoma metastasis. Furthermore, smoking was also associated with other 
adverse prognostic features, including increasing Breslow depth and ulceration. To our 
knowledge, this is the largest study examining smoking as a factor predicting metastasis in 
cutaneous melanoma, and the only study to examine this phenomenon with regard to SLN 
metastasis. These results suggest smoking may promote early dissemination of melanoma to 
regional sites.
Although in the past there has been some suggestion that smoking was associated with an 
increased propensity to early metastasis in some malignancies, the literature is somewhat 
limited. In many large databases and clinical trials, smoking status is not assessed or 
recorded at initial melanoma diagnosis, and it is also generally undermonitored during 
follow-up.9, 12, 13 Despite extensive literature examining clinical and pathologic factors that 
are related to SLN metastasis in melanoma, to our knowledge no study has examined the 
impact of smoking on this process; however, some studies have examined the relationship of 
smoking to nodal metastases in other malignancies, including bladder cancer, renal cell 
cancer, and head and neck cancers.14–18 Lynch and colleagues identified a greater than 10 
pack-year smoking history as a risk factor for contralateral nodal recurrence in tonsillar 
cancer.15 In a predictive model assessing clinicopathologic, molecular, and genetic 
characteristics in clear cell renal cell carcinoma, Kroeger and colleagues identified smoking 
as independently associated with increased lymphatic spread.18 Lung, pancreatic, breast, 
prostate, colon, bladder, esophageal, and oral cancers have also been reported to have an 
association with smoking and the potential for either metastatic spread or progression.17–25
The mechanisms responsible for this effect are not yet known, but several plausible 
hypotheses exist. Smoking may increase SLN metastasis by enhancing immunosuppressive 
factors in the tumor’s microenvironment.26–31 For example, carboxyhemoglobinemia from 
carbon monoxide contained in tobacco smoke produces a prolonged hypoxic state, and 
tumor hypoxia is associated with increased metastasis and mortality in several 
malignancies.2 Hypoxia can also upregulate programmed death-ligand 1 (PD-L1) expression 
on myeloid suppressor cells, macrophages, dendritic cells and tumor cells, promote 
regulatory T-cell abundance, and increase lactate secretion.27–30
Our analysis is limited by its reliance on self-reported smoking history and the lack of 
prospective, objective, and systematized quantitative smoking assessments. Such 
information, obtained from very large patient cohorts, might be able to demonstrate a dose-
response relationship, and would be an interesting area of future research.32, 33 Future study 
and clinical databases should include more detailed quantitative smoking assessments such 
as ‘pack year’ data, number of smoking years, and time interval since quitting. In addition, 
more precise details on type of tobacco products used should be recorded in the future. A 
dose response relationship with regard to SLN metastasis was not identified in this study; 
however, quantitative smoking history was incomplete and deemed less reliable. In the data 
set, 11.6% of patients were missing pack-year data, 7.3% were missing data regarding 
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cigarettes consumed per day, and 10% were missing data pertaining to years smoked. We 
also did not capture data on ‘passive smoking’ (exposure to cigarette smoke produced by 
others). Utilization of biomarkers for assessment of smoke exposure might help overcome 
these limitations. There may also be other as yet unquantified variables, such as ultraviolet 
radiation exposure, that could be associated with smoking behavior which were not captured 
in our data set.34 Unassessed social factors potentially associated with smoking behavior 
could also be responsible for our findings. These may include decreased health literacy, poor 
treatment compliance, and diminished access to medical care, among others. Such alternate 
explanations must be considered given the noted adverse prognostic features identified in 
smokers without concomitant increase in melanoma incidence. While it is generally 
assumed these social factors affect trial patients less frequently than the general population, 
we cannot discount alternate etiologies of increased tumor thickness, ulceration, and nodal 
metastasis.
CONCLUSIONS
Despite these weaknesses, our findings indicate that current smoking is associated with an 
increase in the risk of SLN metastasis in melanoma patients and that this effect is 
independent of other risk factors. We therefore believe that smoking at the time of melanoma 
diagnosis should be considered an important risk stratification factor.35 Smoking should be 
investigated as a factor contributing to early metastasis of melanoma and possibly other 
tumor types, and should be considered for inclusion in databases in the future. The limited 
impact of former smoking on SLN positivity suggests a transient and likely reversible effect 
of smoking on the metastatic potential of melanoma. There are obviously many reasons why 
current smokers should quit, but this analysis provides an additional rationale for doing so 
for those who are at risk for melanoma development, particularly those recently diagnosed 
with the disease.
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FIG. 1. 
Demographic and histopathologic characteristics. Analysis of clinicopathologic factors 
associated with sentinel node metastasis in patients from MSLT-I and MSLT-II. p-Values in 
the upper right hand corner pertain to the group overall. *Denotes comparison of the selected 
group versus current smokers, ** denotes comparison of the selected group versus former 
smokers, *** denotes comparison of the selected group versus never smokers
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TABLE 1
Logistic regression model for ulceration
Variable p-value OR 95% CI
Smoking: former versus current <0.001 0.68 0.55, 0.85
Smoking: never versus current <0.001 0.70 0.58, 0.84
Age (continuous)   0.001 1.01 1.00, 1.02
Male versus female   0.618 1.04 0.89, 1.21
Breslow (continuous) <0.001 1.44 1.38, 1.50
Extremity versus head/neck   0.356 1.11 0.89, 1.37
Trunk versus head/neck   0.005 1.35 1.09, 1.66
OR odds ratio, CI confidence interval
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TABLE 2
Regression model for Breslow thickness
Variable p-value Parameter estimate 95% CI
Smoking: never versus current   0.002 −0.25 −0.14, −0.09
Smoking: former versus current   0.219 −0.11 −0.29, 0.07
Ulceration <0.001   1.20   1.08, 1.33
Trunk primary versus head/neck   0.880   0.01 −0.15, 0.18
Extremity versus head/neck   0.098 −0.14 −0.31, 0.03
Age (continuous)   0.004   0.010   0.00, 0.01
Female versus male   0.015 −0.15 −0.27, −0.03
CI confidence interval
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